The healthcare industry generates more data today than ever before. Electronic health records, insurance claims, prescription databases, genomic sequences, and countless other sources create a constant stream of information about patient care. Yet despite this explosion of data, healthcare organizations continue to struggle with a fundamental paradox: an abundance of information but a poverty of insight.
This isn’t a technology problem. It’s a methodology problem that traces back to how the healthcare analytics industry evolved through three distinct eras and where many organizations got stuck along the way. The stakes of getting this right have never been higher.
In today’s healthcare environment, the organizations that can turn comprehensive data into actionable insights faster will determine which patients get access to breakthrough therapies first. Market pressures now require a velocity advantage the ability to compress traditional analytics timelines from months to minutes, enabling Life Sciences teams to act faster and think bigger in their mission to reduce disease burden. This isn’t just about having better data; it’s about achieving the speed of decision-making that modern healthcare demands, and where AI should excel. But it’s become an AI readiness problem.
In the rush to adopt AI, most healthcare and Life Sciences organizations are building it on the same fragmented data foundations that failed in previous eras. At Komodo, we recognized early on that domain-specific AI is the only way to generate effective healthcare insights at scale, so we built our full-stack healthcare analytics platform on a foundation of quality data.
Today, our Healthcare Map® captures nearly three quarters of all prescription activity and half of all medical encounters in the U.S., allowing us to directly observe what’s happening across the country before applying any statistical projections. This unprecedented level of coverage gives us a unique vantage point to examine how the healthcare analytics industry has evolved and where it must go next.
1990 to 2005: The Era of Pill Counting
The first significant era of healthcare analytics was built on a simple premise: tracking prescription sales. This “pill counting” approach served a clear purpose in a retail-dominated world, allowing pharmaceutical companies to manage sales performance and align commercial territories. The methodology was remarkably straightforward: Participating pharmacies reported prescription activity, focusing exclusively on dispensing volumes.
But as medicine evolved toward biologics and personalized therapies tailored to the patient journey, the limitations of this transactional model became impossible to ignore. There was no ability to link prescriptions to individual patients over time, which created fragmented views of healthcare journeys. Critical clinical context why medications were prescribed, their outcomes, patient adherence patterns remained invisible.
2010s: The Patient Data Explosion
The next era was a direct response to the shortcomings of pill counting. The industry recognized the need to understand the patient, leading to widespread adoption of electronic health records (EHR), standardized claims processing, and an explosion of patient-level data assets.
However, this era was marked by a critical flaw: an obsession with simply acquiring any and all patient data, with little regard for how it connected or truly represented the patient population. Companies began putting any random patient-level data asset out there, creating a landscape of poorly connected, fragmented assets. The result was an abundance of “great data” but a poverty of actionable insights. Companies boasted about having access to millions of patient records, but these records often came from unrepresentative samples certain insurance types, geographic regions, or provider systems that were easier to access or more willing to share data.
This opportunistic approach to data acquisition resulted in several critical problems:
- Fragmentation despite ambition: Even when companies successfully acquired different data sources, they often failed to meaningfully connect them or address the underlying sampling biases in each source
- Volume over quality: The focus turned to accumulating patient records rather than ensuring that those records actually represented the populations being studied
- Poor insights despite rich data: Companies had access to detailed clinical information but struggled to generate reliable insights because their data foundation was fundamentally incomplete and biased
Data hoarding also caused what economists might recognize as a false economy: decisions that appear comprehensive in the short term but create larger problems down the line because they’re based on fundamentally incomplete information. Consider clinical trial recruitment, where 80% of trials fail to meet their enrollment targets.¹ Using incomplete data to identify potential patients results in delayed trials, increased costs, and postponed access to potentially life-saving treatments. Or consider research studies that inform regulatory decisions and clinical guidelines. When these studies are based on data that systematically excludes certain populations of rural patients, those with specific insurance types, or patients receiving care in particular settings the resulting insights may not apply to the very populations most in need of better treatments.
2025: The Era of the Evidentiary Standard
Today, Komodo is leading a new era that prioritizes representativeness and methodological rigor over data volume. By establishing the Evidentiary Standard, we’re proving that true healthcare intelligence can only emerge from complete, unified patient journeys built on a foundation of comprehensive, representative coverage.
Our goal was never simply to build the largest healthcare dataset. In order to fulfill our mission of reducing the global burden of disease, we set out to develop a full-stack healthcare intelligence platform that would deliver the industry’s richest, most accurate and granular understanding of the patient journey. Instead of acquiring disparate patient data, we spent a decade developing the expertise to correct for inherent sampling bias and transformed raw data into reliable, longitudinal patient journeys. More than just better data, we deliver evidentiary-grade insights built on our industry-leading Healthcare Map and its three defining pillars:
- Representative: We directly observe three out of every four prescription events and half of all medical encounters happening across the country before applying any statistical projections. Our Healthcare Map seamlessly combines data from pharmacies, medical claims, EHR, labs, and more through sophisticated integration technologies
- Highly characterized: Our data contains the deepest clinical context on the market, with linkages to 80% of all U.S. mortality records and race and ethnicity data for over 65% of the patient population
- Statistically rigorous: We’ve built a credible, representative network of data sources and applied rigorous statistical methods to address known gaps and biases. This includes advanced entity resolution and bias correction techniques that go beyond simple matching, and we employ sophisticated algorithms to connect patient journeys across disparate systems without relying on direct identifiers
Data Quality As the Foundation of Medical Innovation
The healthcare industry stands at a critical juncture. As AI and machine learning reshape how we analyze patient data, one truth remains constant: Sophisticated algorithms are only as good as the data they’re trained on. Healthcare transformation won’t be shaped by organizations that have the most data; it will be led by those that combine comprehensive, representative data with methodological rigor that patients deserve.
In Part 2 of this series, we’ll explore how Komodo’s Evidentiary Standard transforms every aspect of healthcare operations and why the future belongs to organizations that prioritize data quality and representativeness over volume and computational power alone.
To see more articles like this, follow Komodo Health on LinkedIn, YouTube, or X, and visit our Resources Hub.
¹ Desai M. Recruitment and retention of participants in clinical trials: Critical issues and challenges. Perspect Clin Res. 2020;11(2):51–53. doi: 10.4103/picr.PICR_6_20
